GINA 2023 lists high BEC as a predictor of asthma response to anti-IgE, anti-IL5/5R, anti-IL4Rα, and anti-TSLP therapies for those with severe asthma and exacerbations in the last year (41) based on reported evidence of a strong association between pre-biologic BEC and post-biologic improvement in exacerbations (8, 42). The gene discussed is IL4R; the disease is asthma.